ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA, January 11, 2023 — HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA,January 5, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases,

ROCKVILLE, MD and SHENZHEN, CHINA, November 16, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive disease

ROCKVILLE, MD and SHENZHEN, CHINA, October 25, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases